The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Pregabalin: a new anxiolytic
Abstract
Pregabalin (S-[+]-3-isobutylgaba) was designed as a lipophilic GABA (gamma-aminobutyric acid) analogue substituted at the 3'-position in order to facilitate diffusion across the blood-brain barrier. It was originally developed as an anticonvulsant agent, however it has been shown to be effective in the treatment of several disorders including hyperalgesia and behavioural disorders. Although its exact mode of action remains unclear, pregabalin interacts with the same binding site and has a similar pharmacological profile as its predecessor, gabapentin (1-[aminomethyl] cyclohexane acetic acid). Its main site of action appears to be on the alpha(2)delta subunit of voltage-dependent calcium channels, widely distributed throughout the peripheral and central nervous system. Pregabalin appears to produce an inhibitory modulation of neuronal excitability. In healthy volunteers, it is rapidly absorbed with peak blood concentrations within 1 h and it has a bioavailability of approximately 90%. In preclinical trials of anticonvulsant activity, pregabalin is three to ten times more potent than gabapentin. It is well-tolerated and associated with dose-dependent adverse effects (ataxia, dizziness, headache and somnolence) that are mild-to-moderate and usually transient. There are no known pharmacokinetic drug-drug interactions reported to date. Preliminary animal and human studies showed beneficial effects in both ethological and conflict models of anxiety, as well as having some sleep-modulating properties. In Phase II and III trials, pregabalin shows promising anxiolytic action when compared to placebo in generalised anxiety disorder, social phobia and panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Rowbotham, M. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,433
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Past-Year Use of Outpatient Services for Psychiatric Problems in the National Comorbidity Survey
Kessler, R. C., Zhao, S., Katz, S. J., Kouzis, A. C., Frank, R. G., Edlund, M., & Leaf, P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.115 · Cited by 610
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
Fink, K., Dooley, D. J., Meder, W. P., Suman-Chauhan, N., Duffy, S., Clusmann, H., & Göthert, M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00172-1 · Cited by 496
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H.-U. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Field, M. J., Oles, R. J., Lewis, A. S., McCleary, S., Hughes, J., & Singh, L. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701320 · Cited by 326
Cited by
The importance of Green Chemistry in Process Research and Development
Dunn, P. J. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15041c · Cited by 604
Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T.-Z., Bramwell, S., Corradini, L., England, S., Winks, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409066103 · Cited by 591
Pregabalin Pharmacology and Its Relevance to Clinical Practice
Ben‐Menachem, E. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455003.x · Cited by 542
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management
Beyenburg, S., Mitchell, A. J., Schmidt, D., Elger, C. E., & Reuber, M. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.05.014 · Cited by 371
Douglas, J. J., Sevrin, M. J., & Stephenson, C. R. J. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00125 · Cited by 361
Efficacy of pregabalin in acute postoperative pain: a meta-analysis
Zhang, J., Ho, K.-Y., & Wang, Y. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer027 · Cited by 357
Pregabalin: Its Pharmacology and Use in Pain Management
Gajraj, N. M. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000287643.13410.5e · Cited by 343
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289
Nicolas, L. B., Kolb, Y., & Prinssen, E. P. M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.015 · Cited by 234
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Pregabalin: A Review of its Use in Fibromyalgia
Lyseng-Williamson, K. A., & Siddiqui, M. A. A. (2008) · Drugs · doi:10.2165/00003495-200868150-00009 · Cited by 50
Hoge, E. A., Oppenheimer, J. E., & Simon, N. M. (2004) · Focus · doi:10.1176/foc.2.3.346 · Cited by 19
Metadata
- Authors
- Lauria-Horner, B. A., & Pohl, R. B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2003-04
- Volume
- 12
- Issue
- 4
- Pages
- 663-672
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2152775636
- Cited by
- 327
- References
- 48
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.